
EMPA-KIDNEY: Among a wide range of patients w/ CKD who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from CV causes (vs. placebo) ca. 2022 from @NEJM #KidneyWk #Nephpearls 👉🏼 nejm.org/doi/full/10.1056/NE…






